Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System.
Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System.
复制标题
DOI:
10.1016/j.ahj.2016.03.029
复制
发表时间:
2016-09
影响因子:
4.8
通讯作者:
Vaughan Sarrazin MS
中科院分区:
文献类型:
--
作者:
Buck J;Kaboli P;Gage BF;Cram P;Vaughan Sarrazin MS
Although controversial, several prior studies have suggested that oral anticoagulants (OACs) are underused in the US atrial fibrillation (AF) population. Appropriate use of OACs is essential because they significantly reduce the risk of stroke in those with AF. In the >2 million Americans with AF, OACs are recommended when the risk of stroke is moderate or high but not when the risk of stroke is low. To quantify trends and guideline adherence, we evaluated OAC use (either warfarin or dabigatran) in a 10-year period in patients with new AF in the Veterans Health Administration. New AF was defined as at least 2 clinical encounters documenting AF within 120 days of each other and no previous AF diagnosis (N = 297,611). Congestive Heart Failure, Hypertension, Age >75, Diabetes, and Stroke (CHADS2) scores were determined using age and diagnoses of hypertension, diabetes, heart failure, and stroke or transient ischemic attack during the 12 months before AF diagnosis. Receipt of an OAC within 90 days of a new diagnosis of AF was evaluated using VA pharmacy data. Overall, initiation of an OAC fell from 51.3% in 2002 to 43.1% in 2011. For patients with CHADS2 score of 0, 1, 2, 3, 4, and 5–6, the proportions of patients prescribed an OAC showed a relative decrease of 26%, 23%, 14%, 12%, 9%, and 13%, respectively (P >.001). Clopidogrel use was stable at 10% of the AF population. Among US veterans with new AF and additional risk factors for stroke, only about half receive OAC, and the proportion is declining.
登录
查看更多内容
影响因子:
4.8
作者:
Gage, BF;Yan, Y;Radford, MJ
通讯作者:
Radford, MJ
影响因子:
39.3
作者:
Nieuwlaat, Robby;Capucci, Alessandro;Crijns, Harry J. G. M.
通讯作者:
Crijns, Harry J. G. M.
影响因子:
39.3
作者:
Camm, A. John;Lip, Gregory Y. H.;Verheugt, Freek W. A.
通讯作者:
Verheugt, Freek W. A.
DOI:
10.1093/europace/eun369
发表时间:
2009-04
期刊:
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
影响因子:
--
作者:
Nabauer M;Gerth A;Limbourg T;Schneider S;Oeff M;Kirchhof P;Goette A;Lewalter T;Ravens U;Meinertz T;Breithardt G;Steinbeck G
通讯作者:
Steinbeck G
DOI:
10.1016/j.amjmed.2015.05.044
发表时间:
2015-12
期刊:
The American journal of medicine
影响因子:
--
作者:
Barnes GD;Lucas E;Alexander GC;Goldberger ZD
通讯作者:
Goldberger ZD